Aura Biosciences (AURA) Net Income towards Common Stockholders (2020 - 2026)
Aura Biosciences (AURA) posted Net Income towards Common Stockholders of -$33.7 million for Q1 2026, down 142.28% on a QoQ basis from $79.7 million in Q4 2025, and down 22.57% year-over-year from -$43.5 million in Q1 2025.
Aura Biosciences (AURA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Aura Biosciences' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$33.7 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 22.57% year-over-year to -$33.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.2 million (up 92.52% YoY) and the FY2025 annual result came in at -$958000.0, up 98.91% from the prior year.
- Net Income towards Common Stockholders was -$33.7 million for Q1 2026 at Aura Biosciences, down from $79.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $79.7 million in Q4 2025 and bottomed at -$74.3 million in Q1 2022.
- A 5-year average of -$23.0 million and a median of -$22.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 1135.3% — and 2025, when it jumped 396.12%.
- Aura Biosciences' Net Income towards Common Stockholders stood at -$18.4 million in 2022, then declined by 20.4% to -$22.1 million in 2023, then fell by 21.58% to -$26.9 million in 2024, then jumped by 396.12% to $79.7 million in 2025, then plunged by 142.28% to -$33.7 million in 2026.
- Business Quant data shows AURA's Net Income towards Common Stockholders at -$33.7 million in Q1 2026, $79.7 million in Q4 2025, and -$26.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Aura Biosciences | 474.16 Mn | 389.36 Mn | - | -33.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.69 Mn |
| Dec 31, 2025 | 79.67 Mn |
| Sep 30, 2025 | -26.13 Mn |
| Jun 30, 2025 | -27.02 Mn |
| Mar 31, 2025 | -27.48 Mn |
| Dec 31, 2024 | -26.91 Mn |
| Sep 30, 2024 | -21.04 Mn |
| Jun 30, 2024 | -20.34 Mn |
| Mar 31, 2024 | -19.71 Mn |
| Dec 31, 2023 | -22.13 Mn |
| Sep 30, 2023 | -18.51 Mn |
| Jun 30, 2023 | -18.30 Mn |
| Mar 31, 2023 | -17.47 Mn |
| Dec 31, 2022 | -18.38 Mn |
| Sep 30, 2022 | -59.05 Mn |
| Jun 30, 2022 | -40.96 Mn |
| Mar 31, 2022 | -74.30 Mn |
| Dec 31, 2021 | -11.78 Mn |
| Sep 30, 2021 | -22.95 Mn |
| Jun 30, 2021 | -8.80 Mn |